Navigation Links
Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
Date:10/4/2007

ROCKVILLE, Md., Oct. 4 /PRNewswire-USNewswire/ -- A new scientific review released today by HHS' Agency for Healthcare Research and Quality concludes that evidence of benefit is lacking for many common ways of treating osteoarthritis of the knee, including popular dietary supplement ingredients, a common surgical procedure, and injected preparations.

The review found that glucosamine and chondroitin, over-the-counter dietary supplement ingredients that are used widely because of their purported benefits to relieve knee pain caused by osteoarthritis and improve physical functioning, appear to be no more effective than placebos. A placebo is a harmless substance given to selected patients in a clinical trial that looks like the real drug or injection being studied, but which has no medical effect.

The review, which was requested and funded by HHS' Centers for Disease Control and Prevention, also failed to find convincing evidence of benefit from arthroscopic surgery to clean the knee joint with or without removal of debris and loose cartilage.

Published studies generally report that injections with hyaluronan preparations (substances that are intended to improve lubrication of the knee joint) improve scores on patient questionnaires used to measure pain and function. However, the evidence is uncertain because of variation in study quality and difficulty determining whether changes in scores translate into real clinical improvements for patients.

"Millions of Americans seek relief from the pain and reduced mobility caused by osteoarthritis of the knee," said AHRQ Director Carolyn M. Clancy, M.D. "However, they should work with their clinicians to decide the best course of treatment for them based on what has and has not been proven to work."

Osteoarthritis is a widespread, costly disease that wears away the cartilage cushioning the knee joint, causing pain and reducing mobility. Arthritic diseases, which include osteoarthritis, affect an estimated 46 million people in the United States, and at age 64 and older, one in 10 Americans is estimated to have osteoarthritis of the knee. Osteoarthritis and related arthritic conditions cost more than $81 billion a year in medical care, lost wages, and other expenses.

The authors, who were led by David J. Samson, M.S., associate director of the AHRQ-supported Blue Cross and Blue Shield Association Evidence-based Practice Center in Chicago, reviewed findings from 53 randomized clinical trials of glucosamine, chondroitin, and injections with hyaluronan preparations and 23 studies of arthroscopy. The review scrutinized individual studies concerned with these treatments' effects as well as meta-analyses that analyzed the combined evidence of groups of studies.

According to authors, better quality randomized clinical trials are needed to clarify whether these treatments are beneficial. However, given the aging of the population and increasing prevalence of obesity --- both risk factors for osteoarthritis of the knee -- "research on new approaches to prevention and treatment of osteoarthritis of the knee should be a high priority."

For a copy of Treatment of Primary and Secondary Osteoarthritis of the Knee, go to http://www.ahrq.gov/downloads/pub/evidence/pdf/oaknee/oaknee.pdf.


'/>"/>
SOURCE Agency for Healthcare Research & Quality
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
2. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
3. Evidence of Nanoparticles Found in Plaque-Filled Arteries
4. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
5. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
6. British Journal of Cancer Reports Preclinical Evidence of Positive Effect of Rice Bran on Intestinal Cancer
7. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
8. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
9. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
10. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
11. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. ... appointed Paul M. Bisaro as Impax,s President ... Company,s Board, effective March 27, 2017. Mr. Bisaro will ... as Interim President and Chief Executive Officer since December ... generic and branded pharmaceutical experience, Mr. Bisaro, 56, is ...
(Date:3/27/2017)... SAN DIEGO , March 27, 2017 ... biopharmaceutical company focused on developing novel, small molecule drugs across ... Company,s President and Chief Executive Officer, will present a corporate ... April 4 at 3:40pm ET.  The conference will take place ... in New York , NY.  ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 According to ... Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators market was ... by 2022, growing at a CAGR of 3.6% during the forecast period. ... ... Allied Market Research Logo ...
Breaking Medicine Technology:
(Date:3/28/2017)... Angeles, CA (PRWEB) , ... March 28, 2017 ... ... credential, which will be offered by the American Association of Integrative Medicine and ... presentations for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon ... this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss ...
(Date:3/28/2017)... ... ... Public relations pros work hard to earn placements and build a ... results are clear, much of PR is hard to quantify. Goal-setting and measurement are ... firms should always take an all-inclusive approach that takes both traditional and non-traditional factors ...
(Date:3/28/2017)... Atlantic City, NJ (PRWEB) , ... March 28, ... ... annual American Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was ... partners, and their team of professional staff discussed strategies for preventing outbreaks among ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... With expansion ... Marshallville, Georgia, in early March. , The seed processing plant opened in Marshallville in ... since 2016. The new office allows opportunity for transition of Patten Seed operations to ...
Breaking Medicine News(10 mins):